WO2014016439A1 - Method and system for the production of nanoparticles - Google Patents
Method and system for the production of nanoparticles Download PDFInfo
- Publication number
- WO2014016439A1 WO2014016439A1 PCT/EP2013/065937 EP2013065937W WO2014016439A1 WO 2014016439 A1 WO2014016439 A1 WO 2014016439A1 EP 2013065937 W EP2013065937 W EP 2013065937W WO 2014016439 A1 WO2014016439 A1 WO 2014016439A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flow
- nanoparticle precursor
- plasma
- nanoparticles
- flow channels
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/16—Making metallic powder or suspensions thereof using chemical processes
- B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
- B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F2202/00—Treatment under specific physical conditions
- B22F2202/13—Use of plasma
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
Definitions
- the present invention relates to a method and system for the production of conjugated nanoparticles, and more particularly conjugated nanoparticles for pharmaceutical and biomedical applications.
- nanoparticles in the nanometer range with many potential industrial applications. Due to their unique size-dependent properties, nanoparticles offer the possibility to develop both new therapeutic and diagnostic tools.
- Microplasmas are a special class of electrical discharges where at least one dimension is reduced to sub-millimetre length scales. Recently microplasma technology has attracted interest in the area of nanoparticle synthesis due to their stable operation at atmospheric pressure and non-thermal characteristics. These properties make microplasmas suitable for a wide range of materials applications which have been described in a recent review by an inventor of the present invention (see “Microplasmas for nanomaterials synthesis", J. Phys. D: Appl. Phys. 43 (2010) 323001 (21 pp)).
- a method for the production of conjugated nanopartides in a microfluidic device at atmospheric pressure and low temperature in a continuous flow comprising the steps of:
- the fluidic device need not necessarily be microfluidic and the plasma need not necessarily comprise microplasma.
- a microfluidic device comprisi ng one or more flow chan nels for entry of a nanoparticle precursor and a conjugate material
- microplasma reactor for the generation of microplasma, the reactor having one or more electrodes;
- a power supply to provide a voltage to at least one or more of the electrodes
- the nanoparticle precursor is in solution.
- the nanoparticle precursor may be a metal salt, for example, HAuCI 4 , or other such soluble material that is capable of chemical reduction by electrons.
- the conjugation of the nanoparticle precursor with the conjugate material may occur by any covalent or non-covalent/electrostatic means known in standard chemistry.
- Embodiments of the invention may use any one or more of a range of conjugate materials for production of conjugated nanoparticles, more particularly for pharmaceutical and biomedical applications.
- conjugate material may include but are not limited to diagnostic agents, bio-sensing agents, drug delivery carriers, therapeutic drugs and/or prophylactic agents.
- Such drugs or agents may further include, but are not li mited to small molecules, peptides, proteins, lipids, organometallic compounds, nucleic acids, carbohydrates, hormones, silicon and polymer-based conjugates (for example PLGA (Poly(Lactide-co-Glycolide), poly(lactic acid) (PLA) and poly(glycolic acid(PGA)) or any target ligand or drug, metals such as gold, silver, palladium, ruthenium, radioactive compounds, vaccines, immunological agents or combinations thereof.
- PLGA Poly(Lactide-co-Glycolide
- PLA poly(lactic acid)
- PGA poly(glycolic acid
- each flow channel is further provided with an inlet.
- each flow channel is provided with an outlet
- the conjugated nanoparticles can be collected through an outlet of the flow channel and stored for later use. In another embodiment, the conjugated nanoparticles can be used directly for injection in other applications for example as described herein.
- the temperature is preferably low. In one embodiment, the temperature is between 15 to 80°C. In another embodiment, the temperature is the ambient temperature surrounding the system.
- Systems embodying the present invention preferably operate at or around (e.g. substantially at) atmospheric pressure such that they are operable at ambient conditions with no specific need of varying the pressure with pumps or a vacuum system. This has the benefit of reducing the cost of the system, lowering maintenance costs and simplifying the system to reduce the risk of malfunctioning.
- the further advantage of using an atmospheric pressure microplasma system is that it provides a more stable environment for plasma formation compared with large scale plasma systems which often lead to instabilities and gas heating, conditions that are unsuitable for materials applications.
- the microplasma reactor is located within the flow channel which carries the nanoparticle precursor such that a microplasma is in contact with the nanoparticle precursor.
- said electrodes comprise an anode electrode and a cathode electrode.
- the anode electrode may comprise any suitable type of anode such as a metal rod, for example, a stainless steel rod.
- the cathode electrode may comprise any suitable type of cathode, for example, a microcapillary hollow tube.
- the microcapillary tube is made of metal e.g. stainless steel.
- the microcapillary tube is approximately 250 ⁇ in diameter.
- Each electrode may be in direct contact with the nanoparticle precursor, for example, the electrode may be immersed in the nanoparticle precursor solution or the electrode may be located near or on an interface with the nanoparticle precursor solution.
- the microplasma may be generated by electrodes driven by a power supply. By applying a sufficient voltage to one or more electrodes, a region of plasma can be generated.
- Non-thermal, atmospheric-pressure operation makes it possible to couple microplasmas with liquid as well.
- a microplasma is formed at the surface or with a liquid, the ions, electrons and other excited species in the gas phase interact with and initiate reactions in the solution. This approach can be useful to nucleate and grow colloidal nanoparticles or modify the surface chemistry of nanoparticles.
- the power supply has an operating voltage of 1 .2kV and a resistor at 100 kQ.
- Other examples of operational power ranges include but are not limited to; 1 ) frequency in the range dc to microwave; 2) voltage in the range 500 V to 5 kV; 3) current in the range from ⁇ to mA.
- the power supply is in a miniature form.
- the microplasma generation may be coupled with supplied gas flow wherein the gas is introduced into the microplasma reactor through a gas flow inlet.
- the gas is carried through a hollow electrode such as in the form of a microcapillary hollow tube.
- the gas may include but is not limited to any one of following: air, helium or argon.
- the flow channels are of uniform shape. In some embodiments, the width and/or height of each flow channel ranges from approximately 1 ⁇ to approximately 1000 ⁇ . In some embodiments, the length of each flow channel ranges from approximately 100 ⁇ to approximately 10 cm.
- Flow channels may be composed of any material suitable for the flow of fluid through the channels, such as Perspex. Typically, the material is one that is resistant to solvents and non-solvents that may be used in the preparation of nanoparticles and conjugates thereof.
- the flow channels join at a convergence point.
- the nanoparticle precursor flow channel and the conjugate material flow channel converge to form a T-Shape channel or the like to provide optimum interaction of the nanoparticle precursor and conjugate material.
- the system may comprise a mixing means for aiding the interaction between the microplasma and the conjugate material.
- the mixing means may comprise an additional enlarged channel section which forms part of one or more flow channels to help mixing and control flow speed of the nanoparticle formation.
- the mixing means is located proximate to or at the convergence point of the flow channels for supplying the nanoparticle precursor and the conjugating material respectively.
- the application of pressure to the nanoparticle precursor and/or conjugate material causes optimal flow of such fluid through each channel which is controlled by a flow control means.
- the flow control means is a pressure means for aiding the flow of fluid.
- Pressure means may be any suitable means such as a syringe, a microcapillary force, a pump, and/or by gravity.
- the pressure means is regulatable i.e. the applied pressure may be increased, decreased, or held constant.
- the flow rate of the nanoparticle precursor or conjugate material is adjustable and/or regulatable by adjusting the size e.g. length, width, and/or height of the flow channel. The flow rate may be regulated either manually or by automation.
- the dimensions of the system can be approximately 10 cm x 5 cm x 5 cm.
- the system is portable.
- An advantage of continuous flow in preferred embodiments of the present invention is to allow the manufacturing of large quantities of nanoparticle precursors with a fast rate and high yield so as to provide a high throughput.
- Continuous flow is a non-stop process analogous to roll-to-roll type manufacturing.
- the process provides continuous production of conjugated nanoparticles with no need of supervision or intervention beyond the actual collection of nanoparticles.
- Preferred embodiments of the invention provide rapid generation of conjugated nanoparticles, for example within a range from 30 seconds up to a several minutes. In one embodiment, the processing time is approximately 2 minutes.
- the nanoparticle precursor and conjugate material are injected into the microfluidic device through two separate flow channel inlets.
- Microplasma is generated at the electrode(s) and interacts with the nanoparticle precursor.
- the microplasma generation then produces nanoparticle nucleation and growth.
- the synthesized nanoparticles are mixed with the conjugate material. This process allows nanoparticles functionalization and drug attachment. These can then be collected at the outlet or directly used as required.
- a combined microfluidic-microplasma method and system produce bespoke functionalized nanoparticles at atmospheric-pressure and ambient temperature with no need for specific temperature conditions and pressure regulations which are required for chemical synthesis or other nanoparticle synthesis in gas phase.
- a disadvantage of the generation of gas-phase plasma-generated nanoparticles is that the nanoparticles are collected on a substrate initially and conjugated later making the process multi-stepped and prolonged.
- the use of liquid-phase plasma-generated nanoparticles in preferred embodiments of the present invention overcomes this time consuming step as the synthesized nanoparticles remain dispersed in solution. This is also desirable for biological applications such as bio-sensing and drug delivery as they are generally performed in liquid environments and manipulation of conjugated nanoparticles can be done with ease and with no risk of contamination with air.
- the combined microplasma-microfluidic system produces nanoparticles with a controlled size and shape and optimized functionality without the use of damaging reducing agents. This also facilitates the functionalization of the nanoparticles, reduces the steps and enhances the application effectiveness of the nanoparticles. This is particularly critical in the area of therapeutics and drug delivery systems which are dependent on particle size and surface characteristics.
- Preferred embodiments of the present invention are capable of synthesizing conjugated nanoparticles with bespoke characteristics which can be used for many applications such as in therapeutic use, drug delivery, or biosensing applications.
- each conjugated nanoparticle can be synthesized to any bespoke specification for use in such applications by regulating the process parameters; for instance precursor concentration and flow channel size can be manipulated to determine nanoparticle size and shape whilst electrical parameters can control production rate and the degrees of interaction with conjugating materials.
- the method and system of the present invention produce gold nanoparticles.
- Gold nanoparticles exhibit unique Surface Plasmon Resonance (SPR) enhanced properties such as Mie scattering, two-photon luminescence, Surface Enhanced Raman Scattering (SERS). These unique properties are useful for optical diagnostics and detection of cancer.
- SPR Surface Plasmon Resonance
- the SPR can be shifted to the NI R region of the 'biological window' which enables the use of gold nanoparticles in imaging and therapy techniques.
- a further advantage of preferred embodiments is that synthesis and conjugation of nanoparticles is achieved at very low cost with no need for complex chemical procedures and processes.
- Embodiments of the invention typically also provide a very clean process with improved performance and reduced costs that can be operated in any environment such as laboratories, hospitals and clinics by a lay person who is not skilled in the art.
- the invention advantageously may also extend to a modular system and thus viewed from a third aspect, the invention provides a system of the second aspect of the present invention for use with other like modular systems of the second aspect of the invention for the production of conjugated nanoparticles.
- the invention provides conjugated nanoparticle products of the method and systems of the present invention as described herein.
- conjugated nanoparticles produced according to the method and systems of the present invention wherein the conjugated nanoparticles are used for pharmaceutical and biomedical applications.
- Figure 1 shows a schematic diagram of a system for the production of conjugated nanoparticles embodying one aspect of the present invention
- Figure 2 shows a schematic diagram of an alternative embodiment of a system for the production of conjugated nanoparticles embodying one aspect of the present invention
- Figure 3 shows TEM (transmission electron microscopy) images of gold nanoparticles produced using embodiments of the method and system of the present invention
- Figures 4A to 4C show respective size distributions with the radius in nm for three different gold precursor concentrations, namely 4A: 0.2 mM, 4B 1 mM, and 4C 5 mM, of HAuCI precursor.
- a system for the production of conjugated nanoparticles embodying one aspect of the present invention comprising a fluidic device, preferably a microfluidic device 10, an inlet 12 for receiving a nanoparticle precursor 16 (or more than one) and an inlet 14 for receiving a conjugate material 18, for example a conjugate drug.
- a fluidic device preferably a microfluidic device 10
- Either or both of the nanoparticle precursor 16 and conjugate material 18 may be introduced to the system and in particular to the respective inlet 12, 14 by and/or under the control of flow control means, for example a syringe, pump or other pressure device (or injection means) capable of injecting or moving fluid, especially liquid, by pressure.
- any one or both of the nanoparticle precursor 16 and conjugate material 18 are in liquid form, e.g. in solution, but may take other forms
- the device 10 includes a flow channel 20 for the precursor 16 and a flow channel 32 for the conjugate material 18.
- the channels 20, 32 meet at an intersection 34.
- An outlet channel 35 is typically provided, leading to an outlet 38.
- the outlet channel runs between the intersection 34 and the outlet 38.
- the illustrated flow channels 20, 32 are substantially co-linear.
- the outlet flow channel 35 may be substantially perpendicularly disposed to the inlet flow channels 20, 32.
- the channels 20, 32, 35 may form a substantially T-shaped composite channel.
- At least one and preferably all of the channels 20, 32, 35 are shaped and dimensioned to serve as microfluidic channels.
- a typical width and/or height of each flow channel 20, 32, 35 ranges from approximately 1 ⁇ to approximately 1000 ⁇ . In some embodiments, the length of each flow channel 20, 32, 35 ranges from approximately 100 ⁇ to approximately 10 cm.
- the channels 20, 32, 35 may be composed of any material suitable for the flow of fluid through the channels, such as Perspex, and are typically formed in a body of the device 10.
- the channels 20, 32, 35, or any one or more of them conveniently has a substantially uniform cross-section, except where a mixing chamber is provided. In alternative embodiments, any one or all of the channels do not have microfluidic dimensions.
- the device 10 includes a plasma generator 37, preferably a microplasma generator, for example a microplasma reactor.
- the plasma generator 37 typically comprises electrodes, in particular an anode 22 and a cathode 24, connected to an electrical power supply 39, a DC supply in this example.
- the generator 37 typically also includes means for supplying gas to the generator 37 for ionization by the action of the electrodes 22, 24 to produce plasma, preferably microplasma.
- the plasma generator 37 is conveniently located in the device 10 to generate plasma in the nanoparticle precursor flow channel 20. For example this may be achieved by locating the generator 37, or at least the electrodes 22, 24, in the channel 20.
- the nanoparticle precursor 16 is injected into the device 10 via inlet 12 and flows through the precursor flow channel 20.
- the electrode pair i.e. anode 22 and cathode 24 are in this example placed through the flow channel 20.
- the preferred cathode 24 comprises a stainless steel microcapillary tube having an inner diameter of approximately 250 ⁇ and the preferred anode 22 comprises a stainless steel rod. Other types and sizes of anode and/or cathode may alternatively be used.
- the DC power supply 39 is switched on at an operating voltage of 1 .2Kv for an operating period, for example 2 minutes.
- the electrode circuit includes a current limiting resistor which in this example has a resistance of 100 kQ.
- the power supply drives the electrodes 22, 24 to generate microplasma 28.
- microplasma 28 is generated on the interface with the nanoparticle precursor 16 and interacts with the precursor resulting in nucleation and growth of nanoparticles 30.
- gas for creating the microplasma may be supplied via a hollow cathode 24, or by any other convenient means.
- the nanoparticle precursor 16 may comprise a metal salt, for example, HAuCI 4 , or other such soluble material that is capable of chemical reduction by electrons. It is typically in liquid form but may take other forms e.g. fluid (gas), solid or suspension.
- the conjugating drug or other conjugating material 18 is injected into the device 10 via inlet 14 and flows through the conjugate material flow channel 32. At the channel intersection 34 the nanoparticles 30 mix with the conjugated drug/material 18 to cause nanoparticle functionalization and/or drug attachment and to form conj ugated nanoparticles 36.
- the conjugated nanoparticles 36 can be collected at outlet 38 or directly used, as required.
- the conjugating material 18 may comprise a diagnostic agent, bio-sensing agent, drug delivery carrier, therapeutic drug and/or prophylactic agent.
- drugs or agents may further include small molecules, peptides, proteins, lipids, organometallic compounds, nucleic acids, carbohydrates, hormones, silicon and polymer-based conjugates (for example PLGA (Poly(Lactide-co-Glycolide), poly(lactic acid) (PLA) and poly(glycolic acid(PGA)) or any target ligand or drug, metals such as gold, silver, palladium, ruthenium, radioactive compounds, vaccines, immunological agents or combinations thereof. It is typically in liquid form but may take other forms e.g. fluid (gas), solid or suspension.
- the operating temperature of the system and in particular within device 1 0 is advantageously low, for example ambient temperature or between approximately 15 to 80°C.
- the system advantageously operates substantially at atmospheric pressure and as such is operable at ambient conditions.
- the device 10 may include mixing means (not illustrated) for aiding interaction between the microplasma and the conjugate material.
- the mixing means may comprise an enlarged channel section forming part of one or more flow channels 20, 30, 35 to help mixing and control flow speed of the nanoparticle formation.
- Preferably the mixing means is located proximate to or at the intersection 34.
- Figure 2 illustrates a system for the production of conjugated nanoparticles embodying one aspect of the present invention, the system being an experimental example showing the synthesis of gold (Au) nanoparticles using AMP (Atmospheric-pressure Microplasma) in the presence of helium gas prior to conjugation with a conjugate material.
- Au gold
- AMP Admospheric-pressure Microplasma
- the nanoparticle precursor comprises a gold precursor solution 44, e.g. Gold (III) chloride trihydrate (HAuCI 4 .3H 2 0) having a concentration (%) of 0.2 mM in distilled water, held in a tank 45.
- Gold (III) chloride trihydrate HAuCI 4 .3H 2 0
- FIG. 2 is a schematic configuration of part of the apparatus for the generation of the gold nanoparticles prior to conjugation with a conjugate material.
- the anode 42 is immersed in the gold precursor solution 44.
- Helium 46 is passed through a microcapillary cathode 48 at a rate of 25 SCCM (standard cubic centimetres per minute).
- SCCM standard cubic centimetres per minute.
- a current flows through the gold precursor solution 44.
- a microplasma 52 is generated at the interface with the gold precursor solution 44.
- the microplasma 52 interacts with the gold precursor 44 resulting in the formation of gold nanoparticles.
- Figure 3 shows Transmission Electron Microscopy (TEM) images of gold nanoparticles using a method embodying the present invention which show a typical five-fold crystal structure and in this case the particle size is about 80 nm in diameter.
- TEM Transmission Electron Microscopy
- Figures 4A to 4C show respective size distributions of the gold nanoparticles with the radius in nm for three different gold precursor concentrations, i.e. 4A) 0.2 m M of precursor, 4B) 1 mM of precursor, 4B) 5 mM of precursor.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201503017A GB2519483A (en) | 2012-07-27 | 2013-07-29 | Method and system for the production of nanoparticles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1213624.8 | 2012-07-27 | ||
GBGB1213624.8A GB201213624D0 (en) | 2012-07-27 | 2012-07-27 | Method and system for production of conjugated nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014016439A1 true WO2014016439A1 (en) | 2014-01-30 |
Family
ID=46881452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/065937 WO2014016439A1 (en) | 2012-07-27 | 2013-07-29 | Method and system for the production of nanoparticles |
Country Status (2)
Country | Link |
---|---|
GB (2) | GB201213624D0 (en) |
WO (1) | WO2014016439A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
EP2905095A1 (en) * | 2014-02-07 | 2015-08-12 | Toyota Jidosha Kabushiki Kaisha | Method and apparatus for producing core-shell type metal nanoparticles |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
WO2018138042A1 (en) * | 2017-01-26 | 2018-08-02 | University Of Ulster | Method and apparatus for producing nanoscale materials |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007087708A1 (en) * | 2006-01-31 | 2007-08-09 | Mcgill University | Organic nanofluids, method and reactor for synthesis thereof |
-
2012
- 2012-07-27 GB GBGB1213624.8A patent/GB201213624D0/en not_active Ceased
-
2013
- 2013-07-29 WO PCT/EP2013/065937 patent/WO2014016439A1/en active Application Filing
- 2013-07-29 GB GB201503017A patent/GB2519483A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007087708A1 (en) * | 2006-01-31 | 2007-08-09 | Mcgill University | Organic nanofluids, method and reactor for synthesis thereof |
Non-Patent Citations (5)
Title |
---|
"Microplasmas for nanomaterials synthesis", J. PHYS. D: APPL. PHYS., vol. 43, 2010, pages 21 |
"Microplasmas for nanomaterials synthesis", J. PHYS. D: APPL. PHYS., vol. 43, 2010, pages 21, XP020195471 * |
CAO QIN ET AL: "Organic layer-coated metal nanoparticles prepared by a combined arc evaporation/condensation and plasma polymerization process; Synthesis organic layer-coated nanoparticles", PLASMA SOURCES SCIENCE AND TECHNOLOGY, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL, GB, vol. 16, no. 2, 1 May 2007 (2007-05-01), pages 240 - 249, XP020120296, ISSN: 0963-0252, DOI: 10.1088/0963-0252/16/2/005 * |
SRIKANTH H ET AL: "Magnetic studies of polymer-coated Fe nanoparticles synthesized by microwave plasma polymerization", APPLIED PHYSICS LETTERS, AIP, AMERICAN INSTITUTE OF PHYSICS, MELVILLE, NY, US, vol. 79, no. 21, 19 November 2001 (2001-11-19), pages 3503 - 3505, XP012029487, ISSN: 0003-6951, DOI: 10.1063/1.1419237 * |
YANG P ET AL: "Synthesis of intrinsic fluorescent polypyrrole nanoparticles by atmospheric pressure plasma polymerization", APPLIED SURFACE SCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 255, no. 15, 15 May 2009 (2009-05-15), pages 6924 - 6929, XP026093114, ISSN: 0169-4332, [retrieved on 20090317], DOI: 10.1016/J.APSUSC.2009.03.016 * |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447164B2 (en) | 2010-08-06 | 2016-09-20 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9181319B2 (en) | 2010-08-06 | 2015-11-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9937233B2 (en) | 2010-08-06 | 2018-04-10 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US10064959B2 (en) | 2010-10-01 | 2018-09-04 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9657295B2 (en) | 2010-10-01 | 2017-05-23 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US10022425B2 (en) | 2011-09-12 | 2018-07-17 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US10751386B2 (en) | 2011-09-12 | 2020-08-25 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9271996B2 (en) | 2011-12-16 | 2016-03-01 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
US9295689B2 (en) | 2011-12-16 | 2016-03-29 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US9587003B2 (en) | 2012-04-02 | 2017-03-07 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9220792B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aquaporin-5 |
US9233141B2 (en) | 2012-04-02 | 2016-01-12 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9255129B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 |
US9220755B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9216205B2 (en) | 2012-04-02 | 2015-12-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding granulysin |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9149506B2 (en) | 2012-04-02 | 2015-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding septin-4 |
US9114113B2 (en) | 2012-04-02 | 2015-08-25 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding citeD4 |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9095552B2 (en) | 2012-04-02 | 2015-08-04 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9221891B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | In vivo production of proteins |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9089604B2 (en) | 2012-04-02 | 2015-07-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating galactosylceramidase protein deficiency |
US9675668B2 (en) | 2012-04-02 | 2017-06-13 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 |
US9782462B2 (en) | 2012-04-02 | 2017-10-10 | Modernatx, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9814760B2 (en) | 2012-04-02 | 2017-11-14 | Modernatx, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9828416B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9827332B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9061059B2 (en) | 2012-04-02 | 2015-06-23 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating protein deficiency |
US9050297B2 (en) | 2012-04-02 | 2015-06-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP2905095A1 (en) * | 2014-02-07 | 2015-08-12 | Toyota Jidosha Kabushiki Kaisha | Method and apparatus for producing core-shell type metal nanoparticles |
WO2018138042A1 (en) * | 2017-01-26 | 2018-08-02 | University Of Ulster | Method and apparatus for producing nanoscale materials |
US11559839B2 (en) | 2017-01-26 | 2023-01-24 | University Of Ulster | Method and apparatus for producing nanoscale materials |
Also Published As
Publication number | Publication date |
---|---|
GB201503017D0 (en) | 2015-04-08 |
GB201213624D0 (en) | 2012-09-12 |
GB2519483A (en) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014016439A1 (en) | Method and system for the production of nanoparticles | |
US9434006B2 (en) | Composition containing spherical and coral-shaped nanoparticles and method of making same | |
Tien et al. | Novel technique for preparing a nano-silver water suspension by the arc-discharge method | |
Saito et al. | Nanomaterial synthesis using plasma generation in liquid | |
Lin et al. | Microplasma: a new generation of technology for functional nanomaterial synthesis | |
CN111940757B (en) | Device and method for continuously preparing noble metal and alloy nanoparticles thereof | |
US20080220175A1 (en) | Nanoparticles wtih grafted organic molecules | |
US20160288211A1 (en) | Multi-metal particle generator and method | |
US11559839B2 (en) | Method and apparatus for producing nanoscale materials | |
CN110526237B (en) | Device and method for preparing noble metal/graphene composite nano material | |
JP2023528199A (en) | Method for producing gold nanoparticles | |
CN108115148B (en) | Method for preparing liquid nano-gold particles by adopting atmospheric pressure low-temperature plasma plume | |
Kaneko et al. | Creation of nanoparticle–nanotube conjugates for life-science application using gas–liquid interfacial plasmas | |
RU2371381C2 (en) | Method and device for plasmochemical synthesis of nano-objects | |
CN112752608B (en) | Plasma polymerization apparatus | |
RU150504U1 (en) | DEVICE FOR PRODUCING SILVER NANOPARTICLES | |
Sazali et al. | Self-assembled morphology of tripod nanoparticle solutions: the effect of arm length and hydrophobic ratio | |
JP2020084205A (en) | Control method for particle size of metal nanoparticle and method for production of metal nanoparticle | |
Kaneko et al. | Synthesis of nano-bio conjugates for drug delivery systems using gas-liquid interfacial discharge plasmas | |
KR101928842B1 (en) | Manufacturing method of gold nanoparticle with well-defined size through wire explosion in liquid | |
Kaneko et al. | Plasma Structure Control and New-Concept Plasma Process for Novel Nano-Bio Materials | |
RU2404120C2 (en) | Method of producing metal oxide nanoparticles in plasma upflows | |
KR101016524B1 (en) | Method and apparatus of manufacturing the nano-powder compounds and their solution | |
CN116575018A (en) | Device for preparing InAs nanowire array in positioning mode and preparation method | |
Yupengxue et al. | RESEARCH PROGRESS AND KEY ISSUES IN SYNTHESIS OF GOLD AND SILVER NANOPARTICLES AND CARBON QUANTUM DOTS BY PLASMA ELECTROCHEMICAL METHOD |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13766476 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 1503017 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20130729 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1503017.4 Country of ref document: GB |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13766476 Country of ref document: EP Kind code of ref document: A1 |